Skip to main content
. 2020 Sep 21;53(1):93–103. doi: 10.4143/crt.2020.459

Fig. 1.

Fig. 1

Study subjects. ctDNA, circulating tumor DNA; EGFR-TKIs, epidermal growth factor receptor tyrosine kinase inhibitors; NSCLC, non–small cell lung cancer; RE, response-evaluable.